Clinical research
Hutchison China MediTech Limited presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic at the 2019 European Society for Medical Oncology Congress.
Data shared in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)
Merck’s vaunted checkpoint inhibitor Keytruda combined with chemotherapy proved to be more efficacious than chemotherapy alone as neoadjuvant therapy in pre- and post-surgery triple-negative breast cancer patients.
Nicholas Kartsonis, head of clinical research in infectious diseases and vaccines at Merck Research Laboratories, noted that additional treatment options are needed for critically ill patients with respiratory infections.
Immutep Limited announces that the requisite number of predefined patient responses has been exceeded in cohort 1 of Part A) of the TACTI-002 Phase II clinical trial based on an interim analysis.
Adrenomed AG, the vascular integrity company, announced the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock.
Treatment with Erleada plus androgen deprivation therapy resulted in a 25% reduction in the risk of death compared to placebo in prostate cancer patients.
Pfizer announced positive top-line results from the first trial in May.
NorthSea Therapeutics B.V. announces dosing of the first patient with icosabutate in a phase 2b dose ranging study.
Hutchison China MediTech Limited will showcase data from its proprietary clinical programs at the 2019 European Society for Medical Oncology Congress on September 27 to October 1, 2019 in Barcelona, Spain.
PRESS RELEASES